JKGD (1) grant/research support - Dompe pharmaceuticals, SiFi Pharmaceuticals (non-specific); MA-J (1) commissioned work – Genus Pharmaceuticals (non-specific); (2) sponsorship to conferences – Abbvie, Janssen-Cilag, Pfizer, Galderma, Steifel (non-specific); (3) clinical trials - Zymogenetics, Pfizer, Genentech, Johnson & Johnson, Centocor, Novartis (non-specific); (4) grant/research support – Emblation (non-specific); (5) developed non-profit website www.drugrash.co.uk to assist clinicians in management of drug allergy (specific).
from #ENT via xlomafota13 on Inoreader http://ift.tt/1NmDHk0
via IFTTT
Σάββατο 7 Μαΐου 2016
UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016
Αναρτήθηκε από
Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00306932607174,00302841026182
στις
4:10 π.μ.
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου